Sintilimab

AssetAntibody

Monoclonal antibody targeting PD-1 to block interaction with PD-L1 and PD-L2

Stage: Phase 2
Modality: Antibody
Target: PDCD1
Indications: 1
Trials: 1,321
Developers: 1

Indications

1

Diffuse large B-cell lymphoma
Phase 2NOT_YET_RECRUITINGNCT05280626clinicaltrials.gov7 Oct 2026

Targets and what it contains2
Owner and partners1
Trials1,321
Evidence for its targets2
Competitors12
Signals15

Every asset’s record: target, stage, trials and the evidence behind it.

Updated 7 Oct 2026 · 2 sources